CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12,424 enrolled
Drug / intervention
Acetylsalicylic acid +1 moredrug
Likely dose
Acetylsalicylic acid 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02984384
NCT02984384Phase 3Completed
CompareCT.gov

PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients

Major Extremity Trauma Research Consortium·interventional·Posted Dec 6, 2016·Updated May 14, 2024

In Brief

A Phase 3 clinical trial evaluating Acetylsalicylic acid and Low Molecular Weight Heparin (LMWH) for Blood Clot and Trauma. Completed, enrolled 12,424 participants across 21 sites in 2 countries.

Detailed Summary

The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Clot, Trauma
CountriesCanada, United States
CollaboratorsPatient-Centered Outcomes Research Institute

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 6, 2016
Enrollment StartApr 24, 2017
Primary CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.6 years ago

Interventions

Acetylsalicylic aciddrug

The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.

Low Molecular Weight Heparin (LMWH)drug

The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.